Covid19 Clinical Trial
Official title:
Effect of COVID-19 Pandemic on Pediatric Cancer Care
Observational cohort study to assess the effects of COVID19 on pediatric cancer care in Egypt and the Arab World through a survey applied to pediatric oncologists who will be interviewed either directly or through the internet to assess the effect of COVID 19 on pediatric cancer care
Corona viruses are single stranded enveloped RNA viruses with helical capsids. They infect
wide variety of hosts including humans and animals. Coronavirus disease 2019 (COVID-19) was
first described in December 2019 in Wuhan, the capital of China's Hubei province. A novel
corona virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was
identified as the causative organism. On 30 Jan 2020, WHO declared COVID-19 as a Public
Health Emergency of International Concern (PHEIC). Subsequently on 11 March 2020, WHO
declared COVID-19 as a pandemic. On April 30, 2020; 3,239,220 confirmed cases were diagnosed
across the globe with 228,860 deaths. The united states has the highest number of cases
followed by spain and Italy. The first confirmed case of COVID-19 in Egypt was reported on 14
February 2020. As of April 30, 2020, there have been 5,537 confirmed cases, 1381 recovered
and 392 deaths The overall global incidence of cancers in children aged 0-14 years is 140·6
per million, whereas, It's 130.9 per million in Egypt. Although cancer is a rare disease
among children and adolescent, It's one of the leading causes of death. The prognosis of
childhood cancer has significantly improved over the past decades with 5-year survival rates
improved from 58% in the mid-1970 to around 83% in 2008-2014.
Little is known about the effects of COVID-19 on children with cancer. Children with cancer
face numerous challenges during COVID-19 pandemic. Children with cancer are immunocompromised
because of cancer or anti-cancer therapy. They have to be hospitalized to receive their
anti-cancer therapy. The major problem we-as pediatric oncologist- face nowadays is how to
organize pediatric cancer care in the COVID-19 ERA.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |